This was mainly because Zeb enhanced the expression of tumour-associated antigens (MAGE-E1, TRP-1, and CD146) in B16F10 tumour (Fig. 3h–j), induced DC maturation, and upregulated MHC I (H2-Db and H2-Kb) molecules after administration (Fig. 3k, l), which strengthened the antigen presentation ability of DCs and the recognition of tumour cells by T cells. The gene discussed is ZEB1; the disease is neoplasm.